ROBIN L. KAPLAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The report by Durant and colleagues in the February issue (1) is interesting, but, with one exception, their patients are not convincing examples of persons who have developed pulmonary toxicity secondary to carmustine (bischloroethylnitrosourea, BCNU). Nine of the 10 patients were receiving one or more drugs known to produce hypersensitivity reactions or fibrosis simultaneously with carmustine. Only the patient with glioblastoma received no prior or concurrent chemotherapy. In addition, five of the 10 patients (including the patient with glioblastoma) had received prior radiation therapy. However scrupulously the lungs had been shielded, it is difficult to completely exclude
KAPLAN RL. Pulmonary Effects of Carmustine (Bischloroethylnitrosourea, BCNU). Ann Intern Med. ;91:131–133. doi: 10.7326/0003-4819-91-1-131_2
Download citation file:
Published: Ann Intern Med. 1979;91(1):131-133.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use